Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity

E. McLeish; N. Slater; A. Sooda; A. Wilson; J.D. Coudert; T.E. Lloyd; M. Needham

doi:10.1016/j.berh.2022.101761

Back

Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity

Journal article

Open access

Peer reviewed

Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity

E. McLeish, N. Slater, A. Sooda, A. Wilson, J.D. Coudert, T.E. Lloyd and M. Needham

Best Practice & Research Clinical Rheumatology, Vol.36(2), Art. 101761

2022

DOI: https://doi.org/10.1016/j.berh.2022.101761

Files and links (2)

pdf

autoimmunity.pdfDownload View

Published (Version of Record) Open Access

url

Free to Read *No subscription requiredView

Abstract

Inclusion body myositis (IBM) is a slowly progressive muscle disease affecting ageing individuals. IBM presents with a distinctive pattern of weakness involving the quadriceps and finger flexor muscles, although other muscles including pharyngeal muscles become affected over time. Pathological hallmarks of IBM include autoimmune features, including endomysial infiltration by highly differentiated T cells, as well as degenerative features marked by intramyofibre protein aggregates organised into inclusion bodies. Despite some progress in understanding the cellular pathways involved in IBM, it remains untreatable, and the progression of the disease leads to progressive weakness, disability, wheelchair dependency and loss of independence. Therefore, there is an urgent need to improve our understanding of the underlying mechanisms and pathways involved in this disease to identify new treatment targets. Here, we discuss the current understanding of aetiopathogenesis, the interrelationship between autoimmunity and degeneration, and how ageing is a major influencer of both these features.

Details

Title: Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity
Authors/Creators: E. McLeish (Author/Creator) - Murdoch University
N. Slater (Author/Creator) - Murdoch University
A. Sooda (Author/Creator) - Murdoch University
A. Wilson (Author/Creator) - Johns Hopkins Medicine
J.D. Coudert (Author/Creator) - The University of Notre Dame Australia
T.E. Lloyd (Author/Creator) - Johns Hopkins Medicine
M. Needham (Author/Creator) - Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia; Perron Institute for Neurological and Translational Science, Perth, WA, Australia; School of Medicine, University of Notre Dame, Fremantle, WA, Australia; Fiona Stanley Hospital, Department of Neurology, Perth, WA, Australia.
Publication Details: Best Practice & Research Clinical Rheumatology, Vol.36(2), Art. 101761
Publisher: Elsevier Ltd.
Identifiers: 991005541989407891
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

179 File views/ downloads

85 Record Views

18 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.106 Rheumatology; 1.106.1684 Dermatomyositis
Web Of Science research areas: Rheumatology
ESI research areas: Clinical Medicine